0001237899-13-000010.txt : 20130104
0001237899-13-000010.hdr.sgml : 20130104
20130104100056
ACCESSION NUMBER: 0001237899-13-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20130102
FILED AS OF DATE: 20130104
DATE AS OF CHANGE: 20130104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER RD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591-6707
BUSINESS PHONE: 9143477000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Powchik Peter
CENTRAL INDEX KEY: 0001377247
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 13510026
MAIL ADDRESS:
STREET 1: REGENERON PHARMACEUTICALS, INC.
STREET 2: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2013-01-02
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001377247
Powchik Peter
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
SVP Clin Devel & Reg Affairs
Common Stock
2013-01-02
4
M
0
30000.0
21.25
A
44990.0
D
Common Stock
2013-01-02
4
F
0
3584.0
177.82
D
41406.0
D
Common Stock
2013-01-02
4
F
0
12830.0
177.82
D
28576.0
D
Common Stock
2013-01-03
4
S
0
786.0
180.83
D
27790.0
D
Common Stock
2013-01-03
4
S
0
6200.0
181.51
D
21590.0
D
Common Stock
2013-01-03
4
S
0
2300.0
182.29
D
19290.0
D
Common Stock
2013-01-03
4
S
0
4300.0
183.1
D
14990.0
D
Common Stock
1532.0
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
21.25
2013-01-02
4
M
0
30000.0
D
2019-12-18
Common Stock
30000.0
295.0
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 786 shares of Company stock on January 3, 2013 at prices ranging from $180.44 to $180.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
Represents volume-weighted average price of sales of 6,200 shares of Company stock on January 3, 2013 at prices ranging from $181.00 to $181.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
Represents volume-weighted average price of sales of 2,300 shares of Company stock on January 3, 2013 at prices ranging from $182.03 to $182.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
Represents volume-weighted average price of sales of 4,300 shares of Company stock on January 3, 2013 at prices ranging from $183.01 to $180.3.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012.
Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
By: Douglas McCorkle For: /s/**Peter Powchik
2013-01-04
EX-24
2
powchik.txt
EDGAR SUPPORTING DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Leonard Schleifer, Alicia Pantaleo, Beverly Dubs, Stuart
Kolinski, Murray Goldberg, and Douglas McCorkle signing singly, the
undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned in the
undersigned's capacity as a director of Regeneron
Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in
accordance with Section 16(a) of the Securities Exchange Act
of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
and execute any such Form 3, 4, or 5, complete and execute any
amendment or amendments thereto, and timely file such form
with the United States Securities and Exchange Commission and
any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest
of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-act
on behalf of the undersigned pursuant to this Power of
Attorney shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 14th day of May, 2008.
*s/Peter Powchik
----------------
Signature
Peter Powchik
-------------
Print Name